This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ZIOPHARM Reports Fourth Quarter And Full Year 2012 Financial Results

___________________________

1  Non-GAAP net loss is calculated as GAAP net loss less the expense (or plus the income) associated with the change in fair value of the liability-classified warrants. Non-GAAP net loss per share is calculated by dividing the Non-GAAP net loss by the weighted average common shares outstanding.
ZIOPHARM Oncology, Inc.
Condensed Statements of Operations
(in thousands except share and per share data)
(unaudited)
         
  Three Months Ended December 31, Twelve Months Ended December 31,
  2012 2011 2012 2011
         
Revenue  $ 200  $ 200  $ 800  $ 667
         
Operating expenses:        
Research and development  34,982  12,650  83,446  57,083
General and administrative  4,061  3,967  19,523  14,984
Total operating expenses  39,043  16,617  102,969  72,067
         
Loss from operations  (38,843)  (16,417)  (102,169)  (71,400)
         
Other income (expense), net  52  13  (13)  39
Change in fair value of warrants  8,566  3,160  6,050  7,583
Net loss  $ (30,225)  $ (13,244)  $ (96,132)  $ (63,778)
         
         
Basic and diluted net loss per share  $ (0.37)  $ (0.19)  $ (1.22)  $ (0.97)
         
Weighted average common shares outstanding used to compute basic and diluted net loss per share  81,347,231  68,160,207  78,546,112  66,003,789
 
 
ZIOPHARM Oncology, Inc.
Balance Sheet Data
(in thousands)
(unaudited)
     
  December 31, 2012 December 31, 2011
     
Cash and cash equivalents  73,306  104,713
Working capital  61,412  92,742
Total assets  83,404  108,108
Total stockholders' equity   48,445  71,607
CONTACT: For ZIOPHARM
         Nicole Jones
         ZIOPHARM Oncology, Inc.
         617-778-2266
         njones@ziopharm.com
         
         Media Contacts:
         David Schull or Lena Evans
         Russo Partners, LLC
         858-717-2310
         212-845-4262
         david.schull@russopartnersllc.com
         lena.evans@russopartnersllc.com

ZIOPHARM Oncology, Inc. Logo

5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,745.98 -5.41 -0.03%
S&P 500 2,108.63 +0.06 0.00%
NASDAQ 5,128.7850 +17.0520 0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs